Resources Honda, Yasushi, et al
Tirzepatide (Mounjaro / Zepbound) a weekly injectable that acts on both GLP-1 and GIP receptors, offering added benefits for glucose and fat metabolism
Johns, Clay, Nassau, Alachua, Leon Patients from cities including Miami, Tampa, West Palm Beach, Boynton Beach, and Panama City may be eligible for care
The combined metabolic benefits are likely to be important, direct effects on blood vessels and the heart may be important, and there may be additional factors that remain unknown
In this work we review current evidence and argue that combination therapy should be primarily deployed for high-risk patients to maximise cardiorenal benefits, provided cost and access barriers are addressed